Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia
| Data(s) |
2011
|
|---|---|
| Resumo |
ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABLT315I mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that " switch-control" inhibitors block BCR-ABLT315I activity by preventing ABL from switching from the inactive to active conformation. |
| Identificador | |
| Publicador |
Cell Press |
| Relação |
DOI:10.1016/j.ccr.2011.03.019 Packer, Leisl M. & Marais, Richard (2011) Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. Cancer Cell, 19(4), pp. 435-437. |
| Fonte |
School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation |
| Palavras-Chave | #110100 MEDICAL BIOCHEMISTRY AND METABOLOMICS #111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) #B Raf kinase; calcium ion; phosphodiesterase 5A; phosphodiesterase V; unclassified drug; article; calcium cell level; cancer invasion; cell proliferation; controlled study; down regulation; enzyme regulation; human; human cell; melanoma cell; oncogene N r |
| Tipo |
Journal Article |
